1. Lundstrom, K. RNA viruses as tools in gene therapy and vaccine development. Genes (Basel). 10, 1–24 (2019).
2. Ma, C. C., Wang, Z. L., Xu, T., He, Z. Y. & Wei, Y. Q. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol. Adv. 40, 1–14 (2020).
3. Anguela, X. M. & High, K. A. Entering the modern era of gene therapy. Annu. Rev. Med. 70, 273–288 (2019).
4. Tizard, I., Ball, J., Stoica, G. & Payne, S. The pathogenesis of bornaviral diseases in mammals. Anim. Heal. Res. Rev. 17, 92–109 (2016).
5. Berg, M., Johansson, M., Montell, H. & Berg, A. L. Wild birds as a possible natural reservoir of Borna disease virus. Epidemiol. Infect. 127, 173–178 (2001).
6. R Rott, S Herzog, B Fleischer, A Winokur, J Amsterdam, W Dyson, H. K. Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science. 228, 755–756 (1983).
7. McClure, M. A., Thibault, K. J., Hatalski, C. G. & Lipkin, W. I. Sequence similarity between Borna disease virus p40 and a duplicated domain within the paramyxovirus and rhabdovirus polymerase proteins. J. Virol. 66, 6572–6577 (1992).
8. Kolodziejek, J. et al. Genetic clustering of Borna disease virus natural animal isolates, laboratory and vaccine strains strongly reflects their regional geographical origin. J. Gen. Virol. 86, 385–398 (2005).
9. Hornig, M. et al. Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder. Mol. Psychiatry 17, 486–493 (2012).
10. Niller, H. H. et al. Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999–2019: an epidemiological investigation. Lancet Infect. Dis. 20, 467–477 (2020).
11. Korn, K. et al. Fatal encephalitic Borna disease virus 1 in solid-organ transplant recipients. N. Engl. J. Med. 379, 1377–1379 (2018).
12. Liesche, F. et al. The neuropathology of fatal encephalomyelitis in human Borna virus infection. Acta Neuropathol. 138, 653–665 (2019).
13. Klaus Korn, Roland Coras, Tobias Bobinger, Sibylle M Herzog, Hannes Lücking, Robert Stöhr, Hagen B Huttner, Arndt Hartmann, A. E. Fatal encephalitis associated with Borna disease virus 1. N. Engl. J. Med. 379, 1375–1377 (2018).
14. Tomonaga, K., Kobayashi, T. & Ikuta, K. Molecular and cellular biology of Borna disease virus infection. Microbes Infect. 4, 491–500 (2002).
15. Hans, A. et al. Persistent, noncytolytic infection of neurons by Borna disease virus interferes with ERK 1/2 signaling and abrogates BDNF-induced synaptogenesis. FASEB J. 18, 863–865 (2004).
16. Matsumoto, Y. et al. Bornavirus closely associates and segregates with host chromosomes to ensure persistent intranuclear infection. Cell Host Microbe 11, 492–503 (2012).
17. Hirai, Y. et al. Borna disease virus assembles porous cage-like viral factories in the nucleus. J. Biol. Chem. 291, 25789–25798 (2016).
18. Horie, M., Kobayashi, Y., Suzuki, Y. & Tomonaga, K. Comprehensive analysis of endogenous bornavirus-like elements in eukaryote genomes. Philos. Trans. R. Soc. B Biol. Sci. 368, 20120499 (2013).
19. Garoff, H., Hewson, R. & Opstelten, D.-J. E. Virus maturation by budding. Microbiol. Mol. Biol. Rev. 62, 1171–1190 (1998).
20. Perez, M. & de la Torre, J. C. Identification of the Borna disease virus (BDV) proteins required for the formation of BDV-like particles. J. Gen. Virol. 86, 1891– 1895 (2005).
21. Neumann, P. et al. Crystal structure of the Borna disease virus matrix protein (BDV-M) reveals ssRNA binding properties. Proc. Natl. Acad. Sci. U. S. A. 106, 3710–3715 (2009).
22. Kraus, I., Bogner, E., Lilie, H., Eickmann, M. & Garten, W. Oligomerization and assembly of the matrix protein of Borna disease virus. FEBS Lett. 579, 2686–2692 (2005).
23. Chase, G. et al. Borna disease virus matrix protein is an integral component of the viral ribonucleoprotein complex that does not interfere with polymerase activity. J. Virol. 81, 743–749 (2007).
24. Honda, T., Horie, M., Daito, T., Ikuta, K. & Tomonaga, K. Molecular chaperone BiP interacts with Borna disease virus glycoprotein at the cell surface. J. Virol. 83, 12622–5 (2009).
25. Makino, A., Horimoto, T. & Kawaoka, Y. Binding properties of GP1 protein of Borna disease virus. J. Vet. Med. Sci. 71, 243–6 (2009).
26. Gonzalez-Dunia, D., Cubitt, B., Grasser, F. a & de la Torre, J. C. Characterization of Borna disease virus p56 protein, a surface glycoprotein involved in virus entry. J. Virol. 71, 3208–3218 (1997).
27. Gonzalez-Dunia, D., Cubitt, B. & de la Torre, J. C. Mechanism of Borna disease virus entry into cells. J. Virol. 72, 783–8 (1998).
28. Gustin, J. K., Bai, Y., Moses, A. V. & Douglas, J. L. Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 from Associating with the Host Restriction Factor BST2/Tetherin. J. Infect. Dis. 212, S181–S190 (2015).
29. El Najjar, F., Schmitt, A. P. & Dutch, R. E. Paramyxovirus glycoprotein incorporation, assembly and budding: A three way dance for infectious particle production. Viruses 6, 3019–3054 (2014).
30. Jayakar, H. R., Jeetendra, E. & Whitt, M. A. Rhabdovirus assembly and budding. Virus Res. 106, 117–132 (2004).
31. Stitz, L. et al. A functional role for neutralizing antibodies in Borna disease: influence on virus tropism outside the central nervous system. J. Virol. 72, 8884– 8892 (1998).
32. Lennartz, F. et al. Surface glycoprotein of Borna disease virus mediates virus spread from cell to cell. Cell. Microbiol. 18, 340–354 (2016).
33. Bajramovic, J. J. et al. Borna disease virus glycoprotein is required for viral dissemination in neurons. J. Virol. 77, 12222–12231 (2003).
34. Schneider, U., Ackermann, A. & Staeheli, P. A Borna disease virus vector for expression of foreign genes in neurons of rodents. J. Virol. 81, 7293–72966 (2007).
35. Ackermann, A., Guelzow, T., Staeheli, P., Schneider, U. & Heimrich, B. Visualizing viral dissemination in the mouse nervous system, using a green fluorescent protein-expressing Borna disease virus vector. J. Virol. 84, 5438–5442 (2010).
36. Daito, T. et al. A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region. J. Virol. 85, 12170– 12178 (2011).
37. Fujino, K. et al. Generation of a non-transmissive Borna disease virus vector lacking both matrix and glycoprotein genes. Microbiol. Immunol. 61, 380–386 (2017).
38. Komatsu, Y. & Tomonaga, K. Reverse genetics approaches of Borna disease virus: applications in development of viral vectors and preventive vaccines. Curr. Opin. Virol. 44, 42–48 (2020).
39. Sakai, M. et al. Degradation of amyloid β peptide by neprilysin expressed from Borna disease virus vector. Microbiol. Immunol. 62, 467–472 (2018).
40. Komatsu, Y. et al. RNA virus-based episomal vector with a fail-safe switch facilitating efficient genetic modification and differentiation of iPSCs. Mol. Ther.- Methods Clin. Dev. 14, 47–55 (2019).
41. Ikeda, Y. et al. A novel intranuclear RNA vector system for long-term stem cell modification. Gene Ther. 23, 256–262 (2016).
42. Honda, T. et al. Long-term expression of miRNA for RNA interference using a novel vector system based on a negative-strand RNA virus. Sci. Rep. 6, 1–9 (2016).
43. Tokunaga, T., Yamamoto, Y., Sakai, M., Tomonaga, K. & Honda, T. Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses. Antiviral Res. 143, 237–245 (2017).
44. Yamamoto, Y., Tomonaga, K. & Honda, T. Development of an RNA Virus-Based Episomal Vector Capable of Switching Transgene Expression. Front. Microbiol. 10, 1–9 (2019).
45. Komatsu, Y., Tanaka, C., Komorizono, R. & Tomonaga, K. In vivo biodistribution analysis of transmission competent and defective RNA virus-based episomal vector. Sci. Rep. 10, 1–12 (2020).
46. Komatsu, Y., Kakuya, Y. & Tomonaga, K. Production of high-titer transmission- defective RNA virus-based episomal vector using tangential flow filtration. Microbiol. Immunol. 64, 602–609 (2020).
47. Beatrice Cubitt a, Christopher Oldstone a, Juan Valcarcel b, J. C. de la T. RNA splicing contributes to the generation of mature mRNAs of Borna disease virus, a non-segmented negative strand RNA virus. Virus Res. 34, 69–79 (1994).
48. Schneider, P. A., Kim, R. & Lipkin, W. I. Evidence for translation of the Borna disease virus G protein by leaky ribosomal scanning and ribosomal reinitiation. J. Virol. 71, 5614–5619 (1997).
49. Walker, M. P., Jordan, I., Briese, T., Fischer, N. & Lipkin, W. I. Expression and characterization of the Borna disease virus polymerase. J. Virol. 74, 4425–4428 (2000).
50. Kojima, S. et al. Splicing-dependent subcellular targeting of Borna disease virus nucleoprotein isoforms. J. Virol. 93, 1–19 (2019).
51. Zimmermann, V., Rinder, M., Kaspers, B., Staeheli, P. & Rubbenstroth, D. Impact of antigenic diversity on laboratory diagnosis of Avian bornavirus infections in birds. J. Vet. Diagnostic Investig. 26, 769–777 (2014).
52. Richt, R. A., Fu, T., Herden, C., Bause-niedrig, I. & Garten, W. Processing of the Borna disease virus glycoprotein gp94 by the subtilisin-like endoprotease furin. J. Virol. 72, 4528–4533 (1998).
53. Eickmann, M. et al. Maturation of Borna disease virus glycoprotein. FEBS Lett. 579, 4751–4756 (2005).
54. Daito, T., Fujino, K., Watanabe, Y., Ikuta, K. & Tomonaga, K. Analysis of intracellular distribution of Borna disease virus glycoprotein fused with fluorescent markers in living cells. J. Vet. Med. Sci. Japanese Soc. Vet. Sci. 73, 1243–1247 (2011).
55. Kiermayer, S., Kraus, I., Richt, A., Garten, W. & Eickmann, M. Identication of the amino terminal subunit of the glycoprotein of Borna disease virus. 531, 255–258 (2002).
56. Shapiro, J. et al. Localization of endogenous furin in cultured cell lines. J. Histochem. Cytochem. 45, 3–12 (1997).
57. Sasaki, M. et al. Development of a rapid and quantitative method for the analysis of viral entry and release using a NanoLuc luciferase complementation assay. Virus Res. 243, 69–74 (2018).
58. Dixon, A. S. et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol. 11, 400–408 (2016).
59. Tamura, T. et al. Characterization of recombinant Flaviviridae viruses possessing a small reporter tag. J. Virol. 92, 1–19 (2017).
60. Suomalainen, M., Liljeström, P. & Garoff, H. Spike protein-nucleocapsid interactions drive the budding of alphaviruses. J. Virol. 66, 4737–4747 (1992).
61. McCown, M. F. & Pekosz, A. The Influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J. Virol. 79, 3595–3605 (2005).
62. Överby, A. K., Pettersson, R. F. & Neve, E. P. A. The glycoprotein cytoplasmic tail of Uukuniemi virus (Bunyaviridae) interacts with ribonucleoproteins and is sritical for genome packaging. J. Virol. 81, 3198–3205 (2007).
63. Clemente, R. & de la Torre, J. C. Cell-to-cell spread of Borna disease virus proceeds in the absence of the nirus primary receptor and furin-mediated processing of the virus surface glycoprotein. J. Virol. 81, 5968–5977 (2007).
64. Amarasinghe, G. K. et al. Taxonomy of the order Mononegavirales: update 2019. Arch. Virol. 164, 1967–1980 (2019).
65. Komorizono, R., Makino, A., Horie, M., Honda, T. & Tomonaga, K. Sequence determination of a new parrot bornavirus-5 strain in Japan: implications of clade- specific sequence diversity in the regions interacting with host factors. Microbiol. Immunol. 60, 437–441 (2016).
66. Garry, C. E. & Garry, R. F. Proteomics computational analyses suggest that the bornavirus glycoprotein is a class III viral fusion protein ( γ penetrene). Virol. J. 6, 1–10 (2009).
67. White, J. M., Delos, S. E., Brecher, M. & Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43, 189–219 (2008).
68. Weissenböck, H., Sekulin, K., Bakonyi, T., Högler, S. & Nowotny, N. Novel Avian Bornavirus in a Nonpsittacine Species (Canary; Serinus canaria) with Enteric Ganglioneuritis and Encephalitis. J. Virol. 83, 11367–11371 (2009).
69. Rubbenstroth, D. et al. Avian bornaviruses are widely distributed in canary birds (Serinus canaria f. domestica). Vet. Microbiol. 165, 287–295 (2013).
70. Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: A decade of progress. Nat. Rev. Drug Discov. 16, 115–130 (2017).
71. Blau, H. M. & Daley, G. Q. Stem cells in the treatment of disease. N. Engl. J. Med. 380, 1748–1760 (2019).
72. Honda, T. et al. Sustainable tumor-suppressive effect of iPSC-derived eejuvenated T cells targeting cervical cancers. Mol. Ther. 28, 1–12 (2020).
73. Braun, E. & Sauter, D. Furin-mediated protein processing in infectious diseases and cancer. Clin. Transl. Immunol. 8, 1–19 (2019).
74. Zhou, A., Webb, G., Zhu, X. & Steiner, D. F. Proteolytic processing in the secretory pathway. J. Biol. Chem. 274, 20745–20748 (1999).
75. Bederka, L. H., Bonhomme, C. J., Ling, E. L. & Buchmeier, M. J. Arenavirus stable signal peptide is the keystone subunit for glycoprotein complex organization. MBio 5, 1–14 (2014).
76. Moulard, M., Hallenberger, S., Garten, W. & Klenk, H. D. Processing and routage of HIV glycoproteins by furin to the cell surface. Virus Res. 60, 55–65 (1999).
77. Kunz, S., Edelmann, K. H., de la Torre, J. C., Gorney, R. & Oldstone, M. B. A. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 314, 168–178 (2003).
78. Lenz, O., Meulen, J. Ter, Klenk, H. D., Seidah, N. G. & Garten, W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. U. S. A. 98, 12701–12705 (2001).
79. Bolt, G., Pedersen, L. Ø. & Birkeslund, H. H. Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: Role of furin. Virus Res. 68, 25–33 (2000).
80. Zhang, J., Leser, G. P., Pekosz, A. & Lamb, R. A. The cytoplasmic tails of the influenza virus spike glycoproteins are required for normal genome packaging. Virology 269, 325–334 (2000).
81. Takizawa, N., Momose, F., Morikawa, Y. & Nomoto, A. Influenza a virus hemagglutinin is required for the assembly of viral components including bundled vrnps at the lipid raft. Viruses 8, 1–15 (2016).
82. Werner-Keišs, N. et al. Restricted expression of Borna disease virus glycoprotein in brains of experimentally infected Lewis rats. Neuropathol. Appl. Neurobiol. 34, 590–602 (2008).
83. Décembre, E. et al. Sensing of ommature particles produced by Dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells. PLoS Pathog. 10, 1–23 (2014).
84. Sinigaglia, L. et al. Immature particles and capsid-free viral RNA produced by Yellow fever virus-infected cells stimulate plasmacytoid dendritic cells to secrete interferons. Sci. Rep. 8, 1–15 (2018).
85. Rubbenstroth, D. et al. No contact transmission of avian bornavirus in experimentally infected cockatiels (Nymphicus hollandicus) and domestic canaries (Serinus canaria forma domestica). Vet. Microbiol. 172, 146–156 (2014).
86. Marzi, A. et al. The signal peptide of the Ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J. Virol. 80, 6305– 6317 (2006).
87. Yolitz, J. et al. Signal peptide of HIV envelope protein impacts glycosylation and antigenicity of gp120. Proc. Natl. Acad. Sci. U. S. A. 115, 2443–2448 (2018).
88. Asmal, M. et al. A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS One 6, 1–12 (2011).
89. Li, Y., Luo, L., Thomas, D. Y. & Kang, C. Y. The HIV-1 Env protein signal sequence retards its cleavage and down-regulates the glycoprotein folding. Virology 272, 417–428 (2000).
90. Jan, M., Upadhyay, C. & Hioe, C. E. HIV-1 Envelope glycan composition as a key determinant of efficient virus transmission via DC-SIGN and resistance to inhibitory lectins. iScience 21, 413–427 (2019).
91. Sinn, P. L., Sauter, S. L. & McCray, P. B. Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors - Design, biosafety, and production. Gene Ther. 12, 1089–1098 (2005).
92. Shahryari, A. et al. Development and clinical translation of approved gene therapy products for genetic disorders. Front. Genet. 10, 1–25 (2019).
93. Cone, R. D. & Mulligan, R. C. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc. Natl. Acad. Sci. U. S. A. 81, 6349–6353 (1984).
94. Mochizuki, H., Schwartz, J. P., Tanaka, K., Brady, R. O. & Reiser, J. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol. 72, 8873–8883 (1998).
95. Burns, J. C., Friedmann, T., Drievert, W., Burrascano, M. & Yee, J.-K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells (gene therapy/zebrafish). Genetics 90, 8033–8037 (1993).
96. Horie, M. et al. Isolation of avian bornaviruses from psittacine birds using QT6 quail cells in Japan. J. Vet. Med. Sci. 78, 305–308 (2016).
97. Ovanesov, M. V et al. Activation of microglia by borna disease virus infection: in vitro study. J Virol 80, 12141–12148 (2006).
98. Honda, T. et al. Linkage between the leader sequence and leader RNA production in Borna disease virus-infected cells. Virolog
論文の公開元へ
